drugset
Drugs / Humalog® Mix25
last change Jan 2023 re-read 9 days ago

Humalog® Mix25

also known as Ly-Lis25

Protein / enzyme biologic

Developed for
type 1 diabetes mellitus · type 2 diabetes mellitus

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy9 trials
Phase 1 NCT05373212 Comparator May 2022 → Jan 2023 type 2 diabetes mellitus Adocia Completed No outcome recorded
Phase 1 NCT05373186 Comparator May → Dec 2022 — Adocia Completed No outcome recorded
Phase 1 NCT03180710 Comparator Jun → Aug 2017 type 2 diabetes mellitus Adocia Completed No outcome recorded
Phase 1 NCT02915250 Comparator Oct 2016 → Jun 2017 type 2 diabetes mellitus Adocia Completed Met primary
Phase 1 NCT02514954 Comparator Jul → Nov 2015 type 1 diabetes mellitus Adocia Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Humalog Mix 25 “Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus” NCT02514954 ↗
10

“a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020

NCT04023344 ↗

NCT02514850 ↗

NCT02514954 ↗

NCT02915250 ↗

NCT03606018 ↗

NCT03180710 ↗

NCT05373186 ↗

NCT05373212 ↗

NCT01981031 ↗
Known as Ly-Lis25 “a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020
Modality Protein / enzyme biologic “reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020
Route Subcutaneous “Subcutaneous injection of an individualized dose” NCT02514954 ↗